As of 2025-06-24, the Intrinsic Value of Strides Pharma Science Ltd (STAR.NS) is 549.05 INR. This STAR.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 829.90 INR, the upside of Strides Pharma Science Ltd is -33.80%.
The range of the Intrinsic Value is 434.83 - 722.33 INR
Based on its market price of 829.90 INR and our intrinsic valuation, Strides Pharma Science Ltd (STAR.NS) is overvalued by 33.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 434.83 - 722.33 | 549.05 | -33.8% |
| DCF (Growth 10y) | 612.23 - 952.08 | 748.79 | -9.8% |
| DCF (EBITDA 5y) | 1,189.52 - 1,702.92 | 1,422.04 | 71.4% |
| DCF (EBITDA 10y) | 1,119.48 - 1,679.12 | 1,366.77 | 64.7% |
| Fair Value | 904.88 - 904.88 | 904.88 | 9.03% |
| P/E | 971.48 - 1,294.17 | 1,119.38 | 34.9% |
| EV/EBITDA | 705.98 - 1,451.35 | 1,039.65 | 25.3% |
| EPV | 358.04 - 467.81 | 412.93 | -50.2% |
| DDM - Stable | 152.33 - 294.32 | 223.32 | -73.1% |
| DDM - Multi | 302.38 - 466.25 | 367.79 | -55.7% |
| Market Cap (mil) | 76,483.59 |
| Beta | 1.35 |
| Outstanding shares (mil) | 92.16 |
| Enterprise Value (mil) | 93,912.09 |
| Market risk premium | 8.31% |
| Cost of Equity | 17.35% |
| Cost of Debt | 8.79% |
| WACC | 14.78% |